Abstract:
Cervical cancer is one of the most common and deadliest cancers in females worldwide. Despite the treatment methods of surgery, radiotherapy and chemotherapy are maturing, the prognosis of patients with recurrent, advanced or metastatic cervical cancer remains poor. Molecular targeted therapy provides new hope for these patients. This review focuses on the advances in agents targeting vascular endothelial growth factor pathway, epidermal growth factor receptor, mammalian target of rapamycin, histone deacetylases and cyclooxygenase-2 in cervical cancer.

Key words: Cervical cancer, Molecular targeted therapy, Vascular endothelial growth factor, Epidermal growth factor receptor, Mammalian target of rapamycin, Histone deacetylases inhibitors, Cyclooxygenase-2 inhibitor